On December 3, Gelonghui | Chongqing Pharscin Pharmaceutical (002907.SZ) announced that the company recently received the "Drug Registration Certificate" (Certificate No.: 2024S02963) issued by the National Medical Products Administration for the company's product Agomelatine tablets (hereinafter referred to as "the drug").
According to data from Yaozhi.com, the overall market share of Agomelatine tablets in 2023 was 0.924 billion yuan. This drug is a new type of antidepressant, with a mechanism of action that breaks through the traditional monoamine neurotransmitter system. It works by activating melatonin receptors (MT1 and MT2) and antagonizing 5-HT2C receptors, while regulating biological rhythms. Agomelatine tablets obtained marketing approval in the European Union in February 2009 and were launched in China in April 2011. In the 2015 "Chinese Guidelines for the Prevention and Treatment of Depression (Second Edition)" and the 2016 "Canadian Anxiety and Mood Disorders Treatment Network/International Society for Bipolar Disorders Bipolar Disorder Treatment Guidelines", Agomelatine is recommended as a first-line treatment drug for patients with depression and sleep disorders with level 1 evidence rating. As the first drug approved as a melatonin receptor agonist, Agomelatine's unique pharmacological characteristics and mechanisms of action provide patients with another choice of medication.